The Cleveland Clinic
clevelandclinic.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
816
Active
158
Phase 3
31
Total enrollment
447,679
Pipeline matrix
Showing 40 of 52 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sacubitril-Valsartan | — | — | — | — | — | 2 | |
| Orlistat | — | — | — | — | — | 2 | |
| Methadone | — | — | — | — | — | 1 | |
| Zilretta Injectable Product or Placebo | — | — | — | — | — | 1 | |
| Anti-Obesity Pharmacotherapy | — | — | — | — | — | 1 | |
| Early Highly Effective Therapies Group | — | — | — | — | — | 1 | |
| Escalation Therapies Group | — | — | — | — | — | 1 | |
| Continue GLP/GIP | — | — | — | — | — | 1 | |
| Diclofenac | — | — | — | — | — | 1 | |
| Tramadol | — | — | — | — | — | 1 | |
| OnabotulinumtoxinA | — | — | — | — | — | 1 | |
| 0.9 % Normal Saline | — | — | — | — | — | 1 | |
| Phentermine-Topiramate | — | — | — | — | — | 1 | |
| Naltrexone-Bupropion Combination | — | — | — | — | — | 1 | |
| Usual care (standard-of-care) arm | — | — | — | — | — | 1 | |
| CREXONT ER | — | — | — | — | — | 1 | |
| Dexamethasone Ophthalmic Insert | — | — | — | — | — | 1 | |
| Prednisolone Acetate 1% Oph Susp | — | — | — | — | — | 1 | |
| vasopressin - early initiation | — | — | — | — | — | 1 | |
| vasopressin - standard initiation | — | — | — | — | — | 1 | |
| Botulinum toxin A | — | — | — | — | 2 | ||
| Ketorolac | — | — | — | — | 2 | ||
| Triamcinolone | — | — | — | — | — | 2 | |
| Propofol-based total intravenous anesthesia | — | — | — | — | — | 1 | |
| Sevoflurane intravenous anesthesia | — | — | — | — | — | 1 | |
| 2 mg/kg sugammadex | — | — | — | — | — | 1 | |
| 0.07 mg/kg neostigmine | — | — | — | — | — | 1 | |
| dispense of study drug | — | — | — | — | — | 1 | |
| Aspire Needle + Emcyte PureBMC | — | — | — | — | — | 1 | |
| Lidocaine and ketamine | — | — | — | — | — | 1 | |
| Lidocaine | — | — | — | 5 | |||
| Ketamine | — | — | — | — | 4 | ||
| Ruxolitinib Topical Cream | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Sodium Hyaluronate | — | — | — | — | — | 2 | |
| whole lung allergen challenge | — | — | — | — | — | 1 | |
| Giapreza | — | — | — | — | — | 1 | |
| Macrobid® Capsules 100 mg | — | — | — | — | — | 1 | |
| Antibiotics | — | — | — | — | — | 1 | |
| Choline and Aspirin | — | — | — | — | — | 1 |
12 more active programs hidden
Next readouts
- 2022-03
- 2025-12
- 2025-12
- 2026-05
- 2026-05-01
- 2026-05-01
- 2026-06-12
- 2026-06-30
- 2026-08
- 2026-08-01
Top conditions
- Obesity24
- Atrial Fibrillation19
- Surgery12
- Multiple Sclerosis11
- Heart Failure11
- Pain11
- Cardiovascular Diseases11
- Parkinson Disease10
Frequently asked questions about The Cleveland Clinic
- How many clinical trials does The Cleveland Clinic have on ClinicalTrials.gov?
- The Cleveland Clinic is listed as the lead sponsor on 816 clinical trials in ClinicalTrials.gov, 158 of which are currently active (recruiting, enrolling, or ongoing).
- How many of The Cleveland Clinic's trials are in Phase 3?
- 31 of The Cleveland Clinic's trials are in Phase 3, spread across 52 active drug programs.
- What therapeutic areas does The Cleveland Clinic focus on?
- The Cleveland Clinic's most-studied conditions on ClinicalTrials.gov are Obesity, Atrial Fibrillation, Surgery, Multiple Sclerosis, Heart Failure.
- When are The Cleveland Clinic's next clinical trial readouts?
- The Cleveland Clinic has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study”, expected around 2022-03.